预防镰状细胞贫血阴茎异常勃起的对照试验:羟基脲加安慰剂与羟基脲加他达拉非比较
这项随机、对照、双盲2期可行性试验在64例18-40岁、过去12个月至少3次镰状细胞贫血相关阴茎异常勃起事件的男性中,比较固定中等剂量羟基脲加安慰剂(常规治疗组)与加他达拉非(实验组)。主要结局为100%招募率、98.4%保留率和93.5%依从率;中位10个月随访中两组阴茎异常勃起事件率无显著差异,严重不良事件和住院率相似。
要点
- 在镰状细胞贫血男性中开展阴茎异常勃起预防的随机对照试验是可行的。
- 羟基脲加他达拉非组与羟基脲加安慰剂组阴茎异常勃起事件发生率无显著差异。
- 羟基脲治疗期间精子浓度、活力和正常形态显著下降,停药3个月后恢复至治疗前水平。
核心结论
- 在镰状细胞贫血男性中开展阴茎异常勃起预防的随机对照试验是可行的。
- 羟基脲加他达拉非与羟基脲加安慰剂相比,阴茎异常勃起事件发生率无显著差异。
研究设计与样本
- 随机、对照、双盲2期可行性试验,纳入64例18-40岁、过去12个月至少3次镰状细胞贫血相关阴茎异常勃起事件的男性。
- 固定中等剂量羟基脲加安慰剂为常规治疗组,固定中等剂量羟基脲加他达拉非为实验组。
- 通过每日短信获取阴茎异常勃起数据;主要结局指标为招募率100%、保留率98.4%和依从率93.5%。
主要发现
- 中位随访10个月(四分位距3-12个月)期间,常规治疗组和实验组每参与者每月阴茎异常勃起事件分别为2.5次和3.02次,发生率比为0.8(95%CI 0.3-1.9;P=0.654)。
- 两组严重不良事件发生率(P=0.999)和住院率(P=0.289)相似。
- 羟基脲治疗期间精子浓度、活力和正常形态显著下降,停药3个月后恢复至羟基脲治疗前水平。
- 事后单臂前后分析显示,与随机化前发生率相比,常规治疗组阴茎异常勃起发生率降低58.3%(从每月5.9次降至2.5次;差值3.4;95%CI 1.1-5.8;P=0.005)。
- 事后单臂前后分析显示,与随机化前发生率相比,实验组阴茎异常勃起发生率降低66.3%(从每月8.9次降至3.02次;差值5.9;95%CI 3.4-8.5;P<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recurrent ischemic priapism is a common complication of sickle cell anemia (SCA) and is associated with devastating physical and psychosocial consequences. All previous trials for priapism prevention have failed to demonstrate clear efficacy. We conducted a randomized, controlled, double-blind phase 2 feasibility trial comparing fixed moderate-dose hydroxyurea plus placebo (usual-care arm) with fixed moderate-dose hydroxyurea plus tadalafil (experimental arm) in 64 males (aged 18-40 years) with at least 3 episodes of SCA-related priapism in the past 12 months. Priapism data were obtained via daily text messages to the participants. The trial's primary outcome measures were 100% recruitment, 98.4% retention, and 93.5% adherence rates. Over a median of 10 months (interquartile range, 3-12), 2.5 and 3.02 priapism events per participant-month were recorded in the usual-care and the experimental arms, with an incidence rate ratio of 0.8 (95% confidence interval [CI], 0.3-1.9; P = .654). The rates of serious adverse events (P = .999) and hospitalization (P = .289) were similar in the 2 arms. Sperm concentration, motility, and normal morphology significantly decreased on hydroxyurea therapy but recovered to prehydroxyurea levels 3 months after therapy cessation. Post hoc, single-arm, pre-post analysis showed a 58.3% priapism incidence rate reduction in the usual-care arm (5.9-2.5 events per month; difference, 3.4; 95% CI, 1.1-5.8; P = .005) and a 66.3% priapism reduction in the experimental arm (8.9-3.02 events per month; difference, 5.9; 95% CI, 3.4-8.5; P < .001) compared with the prerandomization rates. A randomized controlled trial for priapism prevention is feasible in men with SCA. This trial was registered at www.clinicaltrials.gov as #NCT05142254.
引用
- Idris IM, Yusuf AA, Ismail II, et al. A controlled trial for preventing priapism in sickle cell anemia: hydroxyurea plus placebo vs hydroxyurea plus tadalafil. Blood. 2025. PMID: 40073378. doi:10.1182/blood.2024027898
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。